# Insilico Medicine's AI-designed drug Rentosertib enters Phase III trials for pulmonary fibrosis

> Insilico Medicine has moved Rentosertib, a drug it discovered and designed using artificial intelligence, into Phase III trials for idiopathic pulmonary fibrosis, a progressive and irreversible scarring of the lungs with few good treatments. The late-stage study will enroll 320 patients across China over 52 weeks, anchored at Peking Union Medical College Hospital, marking one of the most advanced tests yet of a fully AI-originated medicine. What makes Rentosertib notable is not just its clinical progress but its pedigree. It is a first-in-class TNIK inhibitor, a target the company surfaced with its PandaOmics platform, then turned into a molecule using its Chemistry42 generative chemistry system. An earlier Phase IIa study showed encouraging dose-dependent effects, enough to justify the expensive leap to Phase III. If the drug succeeds, it would be a meaningful proof point for computational drug discovery, which has long promised to shorten the slow, costly hunt for new medicines. Phase III is where most drugs fail, so the outcome will say a lot about whether AI can help pick better targets and molecules, not just faster ones.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: Drug Target Review · Published Sunday, August 16, 2026_

## Wortins' read

Insilico Medicine has moved Rentosertib, a drug it discovered and designed using artificial intelligence, into Phase III trials for idiopathic pulmonary fibrosis, a progressive and irreversible scarring of the lungs with few good treatments. The late-stage study will enroll 320 patients across China over 52 weeks, anchored at Peking Union Medical College Hospital, marking one of the most advanced tests yet of a fully AI-originated medicine. What makes Rentosertib notable is not just its clinical progress but its pedigree. It is a first-in-class TNIK inhibitor, a target the company surfaced with its PandaOmics platform, then turned into a molecule using its Chemistry42 generative chemistry system. An earlier Phase IIa study showed encouraging dose-dependent effects, enough to justify the expensive leap to Phase III. If the drug succeeds, it would be a meaningful proof point for computational drug discovery, which has long promised to shorten the slow, costly hunt for new medicines. Phase III is where most drugs fail, so the outcome will say a lot about whether AI can help pick better targets and molecules, not just faster ones.

## Source

[Read the full story at Drug Target Review](https://www.drugtargetreview.com/insilico-medicine-launches-phase-iii-trial-of-ai-designed-rentosertib-drug/2135890.article)

## Related coverage

- [Emerald AI Raises $150 Million Series A at $1.05 Billion Valuation](https://www.wortins.com/story/emerald-ai-raises-150-million-series-a-at-1-05-billion-valua-2071899e) — [Business Wire](https://www.businesswire.com/news/home/20260825127649/en/Emerald-AI-Raises-$150-Million-Series-A-at-$1.05-Billion-Valuation-to-Scale-Power-Flexible-AI-Data-Centers)
- [Google Cloud Launches Gemini Enterprise for Financial Services](https://www.wortins.com/story/google-cloud-launches-gemini-enterprise-for-financial-servic-5d0fd141) — [Google Cloud](https://www.googlecloudpresscorner.com/2026-08-25-Google-Cloud-Launches-Gemini-Enterprise-for-Financial-Services)
- [Apple Updates, AI Computers, and OpenAI's Jalapeño Chip](https://www.wortins.com/story/apple-updates-ai-computers-and-openai-s-jalape-o-chip-adb3115c) — [Stratechery](https://stratechery.com/2026/apple-updates-mini-and-studio-ai-computers-openai-jalapeno/)
- [Anthropic Adds Claude Mythos 5 to Claude Security for Vulnerability Scanning](https://www.wortins.com/story/anthropic-adds-claude-mythos-5-to-claude-security-for-vulner-34ff7302) — [Anthropic](https://claude.com/blog/bringing-claude-mythos-5-to-more-defenders)
- [Callosum Raises $100 Million to Match AI Tasks with Most Cost-Effective Models](https://www.wortins.com/story/callosum-raises-100-million-to-match-ai-tasks-with-most-cost-da05cef6) — [Bloomberg](https://www.bloomberg.com/news/articles/2026-08-20/ai-startup-callosum-raises-100-million-to-make-ai-tasks-cheaper)
- [Transfyr Raises $25 Million Seed for Physical AI Platform](https://www.wortins.com/story/transfyr-raises-25-million-seed-for-physical-ai-platform-163dfbba) — [TechStartups](https://techstartups.com/2026/08/26/startup-funding-news-today-august-26-2026-emerald-ai-gatik-stellaria-more/)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._